Salsalate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318684

CAS#: 552-94-3

Description: Salsalate is a nonsteroidal anti-inflammatory drug, a nonacetylated salicylate with no more problems of gastrointestinal bleeding than placebo. It inhibits synthesis and release of prostaglandins through the inactivation of cyclooxygenase-1 and COX-2. Salsalate is currently being investigated as a treatment for Type 2 diabetes with possible use to prevent the disease in people at risk. It reduces blood glucose concentrations in patients with type 2 diabetes, as well as in insulin-resistant patients without diabetes.


Chemical Structure

img
Salsalate
CAS# 552-94-3

Theoretical Analysis

MedKoo Cat#: 318684
Name: Salsalate
CAS#: 552-94-3
Chemical Formula: C14H10O5
Exact Mass: 258.05282
Molecular Weight: 28.23
Elemental Analysis: C, 65.12; H, 3.90; O, 30.98

Price and Availability

Size Price Availability Quantity
5.0g USD 150.0 2 Weeks
10.0g USD 250.0 2 Weeks
20.0g USD 350.0 2 Weeks
50.0g USD 450.0 2 Weeks
100.0g USD 550.0 2 Weeks
200.0g USD 650.0 2 Weeks
Bulk inquiry

Synonym: Salsalate; Sasapyrine; Salicylsalicylic acid; Disalcid; Disalicylic acid; disalicylic acid; Mono-Gesic; Salsitab; Upsher-Smith brand of salicylsalicylic acid;

IUPAC/Chemical Name: 2-(2-hydroxybenzoyl)oxybenzoic acid

InChi Key: WVYADZUPLLSGPU-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)

SMILES Code: C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 28.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Liang W, Verschuren L, Mulder P, van der Hoorn JW, Verheij J, van Dam AD, Boon
MR, Princen HM, Havekes LM, Kleemann R, van den Hoek AM. Salsalate attenuates
diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and
inflammatory processes. Br J Pharmacol. 2015 Nov;172(22):5293-305. doi:
10.1111/bph.13315. Epub 2015 Oct 22. PubMed PMID: 26292849.

2: Rubin MR, Goldfine AB, McMahon DJ, Donovan DS, Cremers S, Dworakowski E,
Schaefer EJ, Shoelson SE, Silverberg SJ. Effects of the anti-inflammatory drug
salsalate on bone turnover in type 2 diabetes mellitus. Endocrine. 2015
Nov;50(2):504-7. doi: 10.1007/s12020-015-0535-8. Epub 2015 Feb 1. PubMed PMID:
25636441; PubMed Central PMCID: PMC4522229.

3: Ariel D, Kim SH, Liu A, Abbasi F, Lamendola CA, Grove K, Tomasso V, Reaven GM.
Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in
overweight or obese, insulin-resistant, nondiabetic individuals. J Clin Lipidol.
2015 Sep-Oct;9(5):658-63. doi: 10.1016/j.jacl.2015.06.009. Epub 2015 Jun 18.
PubMed PMID: 26350812; PubMed Central PMCID: PMC4594205.

4: Penesova A, Koska J, Ortega E, Bunt JC, Bogardus C, de Courten B. Salsalate
has no effect on insulin secretion but decreases insulin clearance: a randomized,
placebo-controlled trial in subjects without diabetes. Diabetes Obes Metab. 2015
Jun;17(6):608-12. doi: 10.1111/dom.12450. Epub 2015 Mar 12. PubMed PMID:
25683256.

5: van Dam AD, Nahon KJ, Kooijman S, van den Berg SM, Kanhai AA, Kikuchi T,
Heemskerk MM, van Harmelen V, Lombès M, van den Hoek AM, de Winther MP, Lutgens
E, Guigas B, Rensen PC, Boon MR. Salsalate activates brown adipose tissue in
mice. Diabetes. 2015 May;64(5):1544-54. doi: 10.2337/db14-1125. Epub 2014 Dec 4.
PubMed PMID: 25475439.

6: Alderete TL, Sattler FR, Richey JM, Allayee H, Mittelman SD, Sheng X, Tucci J,
Gyllenhammer LE, Grant EG, Goran MI. Salsalate treatment improves glycemia
without altering adipose tissue in nondiabetic obese hispanics. Obesity (Silver
Spring). 2015 Mar;23(3):543-51. doi: 10.1002/oby.20991. Epub 2015 Feb 3. PubMed
PMID: 25644856; PubMed Central PMCID: PMC4340767.

7: Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Ochoa H,
Reaven G. Effect of salsalate on insulin action, secretion, and clearance in
nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled
study. Diabetes Care. 2014 Jul;37(7):1944-50. doi: 10.2337/dc13-2977. PubMed
PMID: 24963111; PubMed Central PMCID: PMC4067392.

8: Goldfine AB, Jablonski KA, Shoelson SE, Creager MA; TINSAL-FMD (Targeting
Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary
Study Team. Response to comment on Goldfine et al. Targeting inflammation using
salsalate in patients with type 2 diabetes: effects on flow-mediated dilation
(TINSAL-FMD). Diabetes care 2013;36:4132-4139. Diabetes Care. 2014
May;37(5):e112. doi: 10.2337/dc14-0222. PubMed PMID: 24757239.

9: Anderson K, Wherle L, Park M, Nelson K, Nguyen L. Salsalate, an old,
inexpensive drug with potential new indications: a review of the evidence from 3
recent studies. Am Health Drug Benefits. 2014 Jun;7(4):231-5. Review. PubMed
PMID: 25126374; PubMed Central PMCID: PMC4105730.

10: Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C,
Monnier VM; TINSAL-T2D Research Consortium. The impact of salsalate treatment on
serum levels of advanced glycation end products in type 2 diabetes. Diabetes
Care. 2014 Apr;37(4):1083-91. doi: 10.2337/dc13-1527. Epub 2013 Nov 19. PubMed
PMID: 24255104; PubMed Central PMCID: PMC3964486.

11: Pierce GL, Siefers K, Wegman-Points L. Comment on Goldfine et al. Targeting
inflammation using salsalate in patients with type 2 diabetes: effects on
flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139. Diabetes
Care. 2014 May;37(5):e110-1. doi: 10.2337/dc13-2781. PubMed PMID: 24757238.

12: Fakhri M, Imani EF, Khalili N. The effect of salsalate on biochemical factors
and endothelial dysfunction of prediabetic patients: A randomized clinical trial.
J Res Med Sci. 2014 Apr;19(4):287-92. PubMed PMID: 25097598; PubMed Central
PMCID: PMC4115341.

13: Wang X, DuBois DC, Cao Y, Jusko WJ, Almon RR. Diabetes disease progression in
Goto-Kakizaki rats: effects of salsalate treatment. Diabetes Metab Syndr Obes.
2014 Aug 1;7:381-9. doi: 10.2147/DMSO.S65818. eCollection 2014. PubMed PMID:
25120374; PubMed Central PMCID: PMC4128793.

14: Nohria A, Kinlay S, Buck JS, Redline W, Copeland-Halperin R, Kim S, Beckman
JA. The effect of salsalate therapy on endothelial function in a broad range of
subjects. J Am Heart Assoc. 2014 Jan 3;3(1):e000609. doi:
10.1161/JAHA.113.000609. PubMed PMID: 24390146; PubMed Central PMCID: PMC3959688.

15: Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski
KA, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2
Diabetes–Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation
using salsalate in patients with type 2 diabetes: effects on flow-mediated
dilation (TINSAL-FMD). Diabetes Care. 2013 Dec;36(12):4132-9. doi:
10.2337/dc13-0859. Epub 2013 Oct 15. PubMed PMID: 24130358; PubMed Central PMCID:
PMC3836144.

16: Jung TW, Youn BS, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Kim BH, Baik SH,
Choi KM. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of
the hepatokine fetuin-A. Biochem Pharmacol. 2013 Oct 1;86(7):960-9. doi:
10.1016/j.bcp.2013.07.034. Epub 2013 Aug 13. PubMed PMID: 23948064.

17: Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M.
Salsalate improves glycemic control in patients with newly diagnosed type 2
diabetes. Acta Diabetol. 2013 Aug;50(4):537-43. doi: 10.1007/s00592-011-0329-2.
Epub 2011 Sep 22. PubMed PMID: 21938543.

18: Summaries for patients. Salsalate for type 2 diabetes mellitus. Ann Intern
Med. 2013 Jul 2;159(1):I-32. doi: 10.7326/0003-4819-159-1-201307020-00001. PubMed
PMID: 23817718.

19: Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson
SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team.
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann
Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.
PubMed PMID: 23817699; PubMed Central PMCID: PMC4128629.

20: Jung TW, Choi HY, Lee SY, Hong HC, Yang SJ, Yoo HJ, Youn BS, Baik SH, Choi
KM. Salsalate and Adiponectin Improve Palmitate-Induced Insulin Resistance via
Inhibition of Selenoprotein P through the AMPK-FOXO1α Pathway. PLoS One. 2013 Jun
18;8(6):e66529. Print 2013. PubMed PMID: 23825542; PubMed Central PMCID:
PMC3689003.